https://www.thebodypro.com/category/adverse-events-comorbidities-hiv/tag/conference-coverage

The Latest

High Hepatitis C Cure Rates With Harvoni and Viekira Pak in Veterans With Genotype 1 Img

High Hepatitis C Cure Rates With Harvoni and Viekira Pak in Veterans With Genotype 1

Hepatitis C regimens containing ledipasvir/sofosbuvir (Harvoni) or paritaprevir/ritonavir/ombitasvir and dasabuvir (Viekira Pak) cured almost 17,500 patients in the Veterans Affairs (VA) health care system.

Eric Lawitz, M.D.

MK3, a One-Pill Triple Direct-Acting Antiviral, Effective for Hepatitis C Genotypes 1, 2, and 3

MK3, a fixed-dose combination of three direct-acting antivirals (DAAs) with different mechanisms of action, provided cure rates exceeding 95% in patients with hepatitis C genotypes 1, 2, or 3.

Hepatitis C Cure Rates Similar Among Specialists, Primary Care Providers, Nurses Img

Hepatitis C Cure Rates Similar Among Specialists, Primary Care Providers, Nurses

Hepatitis C cure rates with ledipasvir/sofosbuvir (Harvoni) proved nearly identical in patients treated by hepatitis specialists, by primary care providers or by nurse practitioners.

Fabienne Laraque, M.D., M.P.H.

Coordinated Care in Poor Neighborhoods Overcomes Some Barriers to Hepatitis C Treatment

A comprehensive, coordinated care program implemented by the New York City Department of Health appeared to reduce barriers to HCV therapy, such as mental health conditions, alcohol or drug use, and HIV infection.

Hepatitis C Cure Rate 93% With Elbasvir/Grazoprevir for Genotype 1 or 4 Img

Hepatitis C Cure Rate 93% With Elbasvir/Grazoprevir for Genotype 1 or 4

Hepatitis C cure rates using elbasvir/grazoprevir (Zepatier) was 93% in individuals with genotypes 1 or 4, in a study of patients in Asia and Russia.

Study author Sofie Hallager presenting the results

Liver Cancer Risk 60% Lower After SVR in Nationwide Danish Study

Cirrhotic hepatitis-C patients in Denmark had a 63% lower risk of liver cancer and a 76% lower risk of decompensated cirrhosis if they achieved a cure with direct-acting antivirals.

Promo Image

Closing the Gap for Tough-to-Treat Hepatitis C Patients

Despite the diversity of new direct-acting antivirals (DAAs), a tiny number of patients are still left behind. Nancy Reau, M.D., presented a summary of soon-to-be-approved drugs that should work for these tough-to-treat patients.

Heart, Kidney, Bone Disease Rates Higher With Than Without HIV Over 2003-2013 Img

Heart, Kidney, Bone Disease Rates Higher With Than Without HIV Over 2003-2013

Prevalence of cardiovascular disease, renal impairment and fractures or osteoporosis was higher with than without HIV every year from 2003 to 2013.

Promo Image

State Medicaid Programs Ease Illegal Restrictions on Hepatitis C Medications, but More Progress Needed

While restrictions for obtaining hepatitis C drugs through Medicaid programs vary state by state, restrictions eased somewhat across the country from 2014 to 2016, according to data presented at the Liver Meeting 2016.

Kidney and Bone Markers Improve After TDF-to-TAF Switch in People 50 or Older Img

Kidney and Bone Markers Improve After TDF-to-TAF Switch in People 50 or Older

Switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) improved kidney and bone markers in a study focused on people 50 years old or older.